Nutrition and exercise during hospital induction for adults with Philadelphia chromosome–negative B‑ALL
Nutrition and Exercise to Optimize Muscle and Adiposity in Adults With ALL: NEOMA ALL Trial
This program will test whether guided nutrition and in-hospital exercise during induction therapy help adults with Philadelphia chromosome–negative B‑ALL keep muscle and limit excess body fat.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06785324 on ClinicalTrials.gov |
What this trial studies
This interventional program enrolls adults newly diagnosed with Philadelphia chromosome–negative B‑cell ALL who are hospitalized for intensive pediatric‑inspired induction chemotherapy. Participants receive a tailored nutrition plan and a supervised in-hospital physical exercise intervention while wearing a Fitbit to record activity. Muscle mass and measures of adiposity will be tracked to see whether the combined interventions better preserve lean tissue and limit fat gain during induction. Patients with BMI ≤18.5, those unable to follow the regimens, or who are pregnant are excluded.
Who should consider this trial
Good fit: Adults with a new diagnosis of Philadelphia chromosome–negative B‑ALL who are receiving inpatient, pediatric‑inspired induction chemotherapy, have BMI >18.5, and are able to follow the diet and exercise plans.
Not a fit: Patients who are underweight (BMI ≤18.5), cannot follow the diet or exercise program, are pregnant, or have medical limitations preventing participation are unlikely to benefit.
Why it matters
Potential benefit: If successful, the interventions could help patients preserve muscle, limit excess fat, and improve physical resilience during and after induction therapy.
How similar studies have performed: Exercise and nutrition interventions have been shown to preserve muscle and improve outcomes in other cancer populations, but using this combined inpatient approach in adults with Ph‑negative B‑ALL is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New Diagnosis of Philadelphia Chromosome Negative B-ALL * Receiving intensive pediatric-inspired induction chemotherapy Exclusion Criteria: * BMI ≤18.5 kg/m2 at time of diagnosis * Unable to comply with both the recommended diet and exercise regimen as deemed by the research or treatment team * Pregnant
Where this trial is running
Chicago, Illinois
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Wendy Stock — University of Chicago
- Study coordinator: Clinical Trials Intake
- Email: cancerclinicaltrials@bsd.uchicago.edu
- Phone: 1-855-702-8222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.